Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Gross Profit | -3.6M | 10.1% |
| Cost of Revenue | 3.6M | 10.1% |
| Operating expense | 5.8M | 14.5% |
| Net Income | -5.8M | 20.2% |
| EBITDA | -5.4M | 15.4% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 6.4M | 13.2% |
| Total Liabilities | 18M | 17.3% |
| Shares Outstanding | 6.5M | 81.9% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | -5.5M | 45.4% |
| Cash from financing | 5.2M | 72.6% |
EPS
Financial Highlights for Calidi Biotherapeutics in Q2 '24
Gross Profit stood at -3.6M, marking a 10.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3.6M, a -10.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 5.8M, showing a -14.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -5.8M, showing a 20.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -5.4M, showing a 15.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
